The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis
Open accessAbstract
BACKGROUND: An open-label study indicated that selective depletion of B cells with the use of rituximab led to sustained clinical improvements for patients with rheumatoid arthritis. To confirm these observations, we conducted a randomized, double-blind, controlled study. METHODS: We randomly assigned 161 patients who had active rheumatoid arthritis despite treatment with methotrexate to receive one of four treatments: oral methotrexate (> or =10 mg per week) (control); rituximab (1000 mg on days 1 and 15); rituximab plus cyclophosphamide (750 mg on days 3 and 17); or rituximab plus methotrexate. Responses defined according to the criteria of the American College of Rheumatology (ACR) and the European League against Rheumatism (EULAR) were assessed at week 24 (primary analyses) and week 48 (exploratory analyses). RESULTS: At week 24, the proportion of patients with 50 percent improvement in disease symptoms according to the ACR criteria, the primary end point, was significantly greater with the rituximab-methotrexate combination (43 percent, P=0.005) and the rituximab-cyclophosphamide combination (41 percent, P=0.005) than with methotrexate alone (13 percent). In all groups treated with rituximab, a significantly higher proportion of patients had a 20 percent improvement in disease symptoms according to the ACR criteria (65 to 76 percent vs. 38 percent, P< or =0.025) or had EULAR responses (83 to 85 percent vs. 50 percent, P< or =0.004). All ACR responses were maintained at week 48 in the rituximab-methotrexate group. The majority of adverse events occurred with the first rituximab infusion: at 24 weeks, serious infections occurred in one patient (2.5 percent) in the control group and in four patients (3.3 percent) in the rituximab groups. Peripheral-blood immunoglobulin concentrations remained within normal ranges. CONCLUSIONS: In patients with active rheumatoid arthritis despite methotrexate treatment, a single course of two infusions of rituximab, alone or in combination with either cyclophosphamide or continued methotrexate, provided significant improvement in disease symptoms at both weeks 24 and 48.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In humans, a reversible depletion of normal B cells is a well-tolerated side effect of the anti-CD20 antibody rituximab, which is an efficacious therapy in mature B cell neoplasms and in autoimmune disease”
From The transcriptional cofactor TRIM33 prevents apoptosis in B lymphoblastic leukemia by deactivating a single enhancer (2015) · cites this paper as Edwards et al., 2004
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevoo, M. L. L., Hof, M. A. V., Kuper, H. H., Leeuwen, M. A. V., van de Putte, L. B. A., & van Riel, P. L. C. M. (1995) · Arthritis & Rheumatism · doi:10.1002/art.1780380107 · Cited by 6,250
Measurement of patient outcome in arthritis
Fries, J. F., Spitz, P. W., Kraines, R. G., & Holman, H. R. (1980) · Arthritis & Rheumatism · doi:10.1002/art.1780230202 · Cited by 4,404
Cytokine Pathways and Joint Inflammation in Rheumatoid Arthritis
Choy, E., & Panayi, G. S. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103223441207 · Cited by 2,248
Felson, D. T., Anderson, J. J., Boers, M., Bombardier, C., Chernoff, M., Fried, B. J., Fürst, D. E., Goldsmith, C. H., Kieszak, S. M., Lightfoot, R. W., et al. (1993) · Arthritis & Rheumatism · doi:10.1002/art.1780360601 · Cited by 1,639
T Cell Activation in Rheumatoid Synovium Is B Cell Dependent
Takemura, S., Klimiuk, P. A., Braun, A. B., Goronzy, J. J., & Weyand, C. M. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.8.4710 · Cited by 536
Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes
Edwards, J., & Cambridge, G. (2001) · Lara D. Veeken · doi:10.1093/rheumatology/40.2.205 · Cited by 525
Self-citationClinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion
Leandro, M. J., Edwards, J. C. W., & Cambridge, G. (2002) · Annals of the Rheumatic Diseases · doi:10.1136/ard.61.10.883 · Cited by 344
Self-citationvan Gestel, A. M., Anderson, J. J., van Riel, P. L. C. M., Boers, M., HAAGSMA, C. J., Rich, B., Wells, G. A., Lange, M., & Felson, D. T. (1999) · PubMed · Cited by 250
Do self‐perpetuating B lymphocytes drive human autoimmune disease?
Edwards, E., Cambridge, & Abrahams (1999) · Immunology · doi:10.1046/j.1365-2567.1999.00772.x · Cited by 174
The role of B cells in rheumatoid arthritis
Dörner, T., & Burmester, G. R. (2003) · Current Opinion in Rheumatology · doi:10.1097/00002281-200305000-00011 · Cited by 164
Research works printed but not linked: 3
- Van Gestel AM, 1999, J Rheumatol, 26, 705
- Tighe H, Carson DA. Rheumatoid factors. In: Kelley WN, Harris ED Jr, Ruddy S, Sledge CB, eds. Textbook of rheumatology. 5th ed. Vol. 1. Philadelphia: W.B. Saunders, 1997:241-9.
- McLaughlin P, 1999, Semin Oncol, 26, 79
Cited by
Sorted by citations
Items 601–700 of 1,000
Clinical Effects and Safety of Rituximab for Treatment of Refractory Pediatric Autoimmune Diseases
El-Hallak, M., Binstadt, B. A., Leichtner, A. M., Bennett, C. M., Neufeld, E. J., Fuhlbrigge, R. C., Zurakowski, D., & Sundel, R. P. (2007) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2006.10.067 · Cited by 72
Srikakulapu, P., & McNamara, C. A. (2017) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00859.2016 · Cited by 73
B cell depletion therapy in systemic lupus erythematosus
Anolik, J. H., Sanz, I., & Looney, R. J. (2003) · Current Rheumatology Reports · doi:10.1007/s11926-003-0020-x · Cited by 72
Rosengren, S., Wei, N., KALUNIAN, K. C., Kavanaugh, A., & Boyle, D. L. (2010) · Lara D. Veeken · doi:10.1093/rheumatology/keq337 · Cited by 71
Singh, J. A., Hossain, A., Tanjong-Ghogomu, E., Mudano, A., Tugwell, P., & Wells, G. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012437 · Cited by 73
Kinase inhibitors: a new class of antirheumatic drugs
Kyttaris, V. C. (2012) · Drug Design Development and Therapy · doi:10.2147/dddt.s25426 · Cited by 70
Rituximab in the Treatment of Pemphigus Vulgaris
Zakka, L. R., Shetty, S., & Ahmed, A. R. (2012) · Dermatology and Therapy · doi:10.1007/s13555-012-0017-3 · Cited by 70
Rituximab in life threatening antisynthetase syndrome
Vandenbroucke, E., Grutters, J. C., Altenburg, J., Boersma, W. G., ter Borg, E. J., & van den Bosch, J. M. M. (2009) · Rheumatology International · doi:10.1007/s00296-009-0859-x · Cited by 70
Cell signalling in macrophages, the principal innate immune effector cells of rheumatoid arthritis
Drexler, S. K., Kong, P. L., Wales, J., & Foxwell, B. M. J. (2008) · Arthritis Research & Therapy · doi:10.1186/ar2481 · Cited by 72
Autologous Stem Cell Transplantation in Autoimmune Diseases
Passweg, J. R., & Tyndall, A. (2007) · Seminars in Hematology · doi:10.1053/j.seminhematol.2007.08.001 · Cited by 70
Managing HBV in patients with impaired immunity
Wursthorn, K., Wedemeyer, H., & Manns, M. P. (2010) · Gut · doi:10.1136/gut.2009.195834 · Cited by 70
Mahmood, Z., Muhammad, K., Schmalzing, M., Roll, P., Dörner, T., & Tony, H.-P. (2015) · Arthritis Research & Therapy · doi:10.1186/s13075-015-0580-y · Cited by 70
Quartuccio, L., Fabris, M., Pontarini, E., Salvin, S., Zabotti, A., Benucci, M., Manfredi, M., Biasi, D., Ravagnani, V., Atzeni, F., et al. (2013) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2012-202435 · Cited by 70
Rituximab Use in Pediatric Central Demyelinating Disease
Beres, S., Graves, J., & Waubant, E. L. (2014) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2014.02.007 · Cited by 69
B cell depletion therapy in autoimmune diseases
Sanz, I. (2006) · Frontiers in bioscience · doi:10.2741/2254 · Cited by 71
Rosengren, S., Wei, N., KALUNIAN, K. C., Zvaifler, N. J., Kavanaugh, A., & Boyle, D. L. (2008) · Arthritis Research & Therapy · doi:10.1186/ar2497 · Cited by 69
Nwosu, C. C., Yau, H. K., & Becht, S. (2015) · Analytical Chemistry · doi:10.1021/ac5040743 · Cited by 68
Fassi, D. E., Nielsen, C. H., Hasselbalch, H. C., & Hegedűs, L. D. (2006) · European Journal of Endocrinology · doi:10.1530/eje.1.02140 · Cited by 69
Rituximab therapy for autoimmune haematological diseases
Barcellini, W., & Zanella, A. (2011) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2010.12.016 · Cited by 68
B cell-targeted therapies in systemic lupus erythematosus
Arbitman, L., Furie, R. A., & Vashistha, H. (2022) · Journal of Autoimmunity · doi:10.1016/j.jaut.2022.102873 · Cited by 72
Innate pathways to B‐cell activation and tolerance
Crampton, S. P., Voynova, E., & Bolland, S. M. (2010) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.05123.x · Cited by 68
Rituximab Therapy for Refractory Orbital Inflammation
Suhler, E. B., Lim, L. L., Beardsley, R. M., Giles, T. R., Pasadhika, S., Lee, S. T., Sardos, A. D. S., Butler, N. J., Smith, J. R., & Rosenbaum, J. T. (2014) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2013.8179 · Cited by 68
Tak, P. P., Mease, P. J., Genovese, M. C., Kremer, J. M., Haraoui, B. P., Tanaka, Y., Bingham, C. O., Ashrafzadeh, A., Travers, H., Safa‐Leathers, S., et al. (2012) · Arthritis & Rheumatism · doi:10.1002/art.33353 · Cited by 68
Sebbag, M., Chapuy‐Regaud, S., Auger, I., Petit, É., Clavel, C., Nogueira, L., Vincent, C., Cornélis, F., Roudier, J., & Serre, G. (2004) · Joint Bone Spine · doi:10.1016/j.jbspin.2004.07.004 · Cited by 68
Drug-Specific Th2 Cells and IgE Antibodies in a Patient with Anaphylaxis to Rituximab
Vultaggio, A., Matucci, A., Nencini, F., Pratesi, S., Petroni, G., Cammelli, D., Alterini, R., Rigacci, L., Romagnani, S., & Maggi, E. (2012) · International Archives of Allergy and Immunology · doi:10.1159/000336839 · Cited by 69
Tebib, J. G., Xavier Mariette, A., Bourgeois, P., Flipo, R., Gaudin, P., Loët, X. L., Gineste, P., Guy, L., Mansfield, C. D., Moussy, A., et al. (2009) · Arthritis Research & Therapy · doi:10.1186/ar2740 · Cited by 68
Beum, P. V., Lindorfer, M. A., Hall, B. E., George, T. C., Frost, K., Morrissey, P., & Taylor, R. P. (2006) · Journal of Immunological Methods · doi:10.1016/j.jim.2006.09.012 · Cited by 68
Park, J. K., Byun, J., Park, J. A., Kim, Y.-Y., Lee, Y. J., Oh, J. I., Jang, S. Y., Kim, Y., Song, Y. W., Son, J., et al. (2016) · Arthritis Research & Therapy · doi:10.1186/s13075-016-0988-z · Cited by 68
B cells and their cytokine activities implications in human diseases
Fillatreau, S. (2017) · Clinical Immunology · doi:10.1016/j.clim.2017.07.020 · Cited by 71
Biomarkers in Rheumatoid Arthritis
Shapiro, S. C. (2021) · Cureus · doi:10.7759/cureus.15063 · Cited by 67
Short- and Long-Lived Autoantibody-Secreting Cells in Autoimmune Neurological Disorders
Zografou, C., Vakrakou, A. G., & Stathopoulos, P. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.686466 · Cited by 67
Evolution of Anti-B Cell Therapeutics in Autoimmune Neurological Diseases
Stathopoulos, P., & Dalakas, M. C. (2022) · Neurotherapeutics · doi:10.1007/s13311-022-01196-w · Cited by 68
Rituximab for the treatment of rheumatoid arthritis
Bagust, A., Boland, A., Hockenhull, J., Fleeman, N., Greenhalgh, J., Dundar, Y., Proudlove, C., Kennedy, T. M., Moots, R. J., Williamson, P. R., et al. (2009) · Health Technology Assessment · doi:10.3310/hta13suppl2/04 · Cited by 67
The Bcl-2 Family Antagonist ABT-737 Significantly Inhibits Multiple Animal Models of Autoimmunity
Bardwell, P. D., Gu, J., McCarthy, D., Wallace, C. D., Bryant, S. H., Goess, C., Mathieu, S., Grinnell, C., Erickson, J., Rosenberg, S. H., et al. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0802813 · Cited by 67
Nakachi, S., Sumitomo, S., Tsuchida, Y., Tsuchiya, H., Kono, M., Kato, R., Sakurai, K., Hanata, N., Nagafuchi, Y., Tateishi, S., et al. (2017) · Arthritis Research & Therapy · doi:10.1186/s13075-017-1309-x · Cited by 69
Role of CXCL13 and CCL20 in the recruitment of B cells to inflammatory foci in chronic arthritis
Armas‐González, E., Domínguez‐Luis, M. J., Díaz-Martín, A., Arce‐Franco, M., Castro‐Hernández, J., Danelon, G., Hernández-Hernández, V., Bustabad, S., Cantabrana, A., Uguccioni, M., et al. (2018) · Arthritis Research & Therapy · doi:10.1186/s13075-018-1611-2 · Cited by 67
Immunopathogenic Mechanisms and Novel Immune-Modulated Therapies in Rheumatoid Arthritis
Chen, S., Lin, G., Chen, J.-W., Wang, K., Tien, C., Hu, C.-F., Chang, C.-N., Hsu, W.-F., Fan, H., & Sytwu, H. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20061332 · Cited by 67
Targeting BAFF: Immunomodulation for autoimmune diseases and lymphomas
Sutherland, A. P. R., Mackay, F., & Mackay, C. R. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2006.06.002 · Cited by 67
Effectiveness of Biologic Therapies for Rheumatoid Arthritis: An Indirect Comparisons Approach
Devine, E., Alfonso-Cristancho, R., & Sullivan, S. D. (2011) · Pharmacotherapy · doi:10.1592/phco.31.1.39 · Cited by 76
JAK Inhibitors and Modulation of B Cell Immune Responses in Rheumatoid Arthritis
Moura, R. A., & Fonseca, J. E. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2020.607725 · Cited by 67
B Cells in Systemic Lupus Erythematosus
Canny, S., & Jackson, S. W. (2021) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2021.04.006 · Cited by 66
Maglione, P. J., Ko, H. M., Beasley, M. B., Strauchen, J. A., & Cunningham‐Rundles, C. (2013) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2013.08.022 · Cited by 67
Current status on B-cell depletion therapy in autoimmune diseases other than rheumatoid arthritis
Dörner, T., Isenberg, D. A., Jayne, D. R. W., Wiendl, H., Zillikens, D., & Burmester, G. R. (2009) · Autoimmunity Reviews · doi:10.1016/j.autrev.2009.08.007 · Cited by 65
Glaesener, S., Quách, T. D., Onken, N., Weller‐Heinemann, F., Dressler, F., Huppertz, H., Thon, A., & Meyer‐Bahlburg, A. (2014) · Arthritis & Rheumatology · doi:10.1002/art.38736 · Cited by 66
B cell depletion therapy in rheumatic disease
Edwards, J., Cambridge, G., & Leandro, M. J. (2006) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2006.05.010 · Cited by 66
Self-citationTrouvin, A., Jacquot, S., Grigioni, S., Curis, E., Dedreux, I., Roucheux, A., Boulard, H., Vittecoq, O., Loët, X. L., Boyer, O., et al. (2014) · Clinical & Experimental Immunology · doi:10.1111/cei.12481 · Cited by 65
Li, J., Ju, Y., Bouta, E. M., Xing, L., Wood, R. W., Kuzin, I. I., Bottaro, A., Ritchlin, C. T., & Schwarz, E. M. (2012) · Arthritis & Rheumatism · doi:10.1002/art.37709 · Cited by 65
Advances in the treatment of rheumatoid arthritis
Vivar, N., & van Vollenhoven, R. (2014) · F1000Prime Reports · doi:10.12703/p6-31 · Cited by 59
Lal, P. G., Su, Z., Holweg, C. T. J., Silverman, G. J., Schwartzman, S., Kelman, A., Read, S., Spaniolo, G., Monroe, J. G., Behrens, T. W., et al. (2011) · Arthritis & Rheumatism · doi:10.1002/art.30596 · Cited by 65
Safety of Biologic Therapy in Rheumatoid Arthritis and Other Autoimmune Diseases: Focus on Rituximab
Fleischmann, R. (2008) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2008.01.001 · Cited by 65
Vita, S. D., Quartuccio, L., & Fabris, M. (2008) · Autoimmunity Reviews · doi:10.1016/j.autrev.2008.05.005 · Cited by 65
Biologics : Target - specific treatment of systemic and cutaneous autoimmune diseases
Raychaudhuri, S. P., & Raychaudhuri, S. (2009) · Indian Journal of Dermatology · doi:10.4103/0019-5154.53175 · Cited by 64
Chang, Y., Wu, Y., Wang, D., Wei, W., Qin, Q., Xie, G., Zhang, L., Yan, S., Chen, J., Wang, Q., et al. (2010) · Lara D. Veeken · doi:10.1093/rheumatology/keq404 · Cited by 65
Chistiakov, D. A., Orekhov, A. N., & Bobryshev, Y. V. (2016) · Immunobiology · doi:10.1016/j.imbio.2016.05.010 · Cited by 66
PTPN22 inhibition resets defective human central B cell tolerance
Schickel, J., Kuhny, M., Baldo, A., Bannock, J. M., Massad, C., Wang, H., Katz, N., Oe, T., Menard, L. C., Soulas-Sprauel, P., et al. (2016) · Science Immunology · doi:10.1126/sciimmunol.aaf7153 · Cited by 65
Current and Future Immunomodulation Strategies to Restore Tolerance in Autoimmune DiseasesPreprint
Bluestone, J. A., & Bour-Jordan, H. (2012) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a007542 · Cited by 67
An open‐label trial of rituximab (Rituxan®) in multifocal motor neuropathy
Chaudhry, V., & Cornblath, D. R. (2010) · Journal of the Peripheral Nervous System · doi:10.1111/j.1529-8027.2010.00270.x · Cited by 64
Aldeghaither, D. S., Smaglo, B. G., & Weiner, L. M. (2015) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.407 · Cited by 68
Rituximab for Intraocular Lymphoma
Itty, S., & Pulido, J. S. (2009) · Retina · doi:10.1097/iae.0b013e318192f574 · Cited by 64
Ocrelizumab: a step forward in the evolution of B-cell therapy
Kausar, F., Mustafa, K. N., Sweis, G. J., Sawaqed, R., Alawneh, K. M., Salloum, R., Badaracco, M. E., Niewold, T. B., & Sweiss, N. (2009) · Expert Opinion on Biological Therapy · doi:10.1517/14712590903018837 · Cited by 64
Rituximab-induced direct inhibition of T-cell activation
Stroopinsky, D., Katz, T., Rowe, J. M., Melamed, D., & Avivi, I. M. (2012) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-011-1168-2 · Cited by 64
DiJoseph, J. F., Dougher, M. M., Armellino, D. C., Kalyandrug, L. B., Kunz, A., Boghaert, E. R., Hamann, P. R., & Damle, N. K. (2006) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-006-0260-5 · Cited by 64
Thurlings, R. M., Vos, K., Gerlag, D. M., & Tak, P. P. (2008) · Arthritis & Rheumatism · doi:10.1002/art.24035 · Cited by 64
Feldmann, M., & Pusey, C. D. (2006) · Journal of the American Society of Nephrology · doi:10.1681/asn.2005121359 · Cited by 64
Gupta, A. K., Gupta, P., & Bajpai, G. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e26125 · Cited by 82
Askenase, P. W., Itakura, A., Leite‐de‐Moraes, M., Lisbonne, M., Roongapinun, S., Goldstein, D. R., & Szczepanik, M. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.10.6390 · Cited by 63
Vannucchi, G. M., Campi, I., Bonomi, M., Covelli, D., Dazzi, D., Currò, N., Simonetta, S., Bonara, P., Persani, L., Guastella, C., et al. (2010) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2010.04191.x · Cited by 63
Das, U. N. (2010) · Journal of Inflammation Research · doi:10.2147/jir.s9425 · Cited by 63
Hartgring, S. A. Y., Willis, C. R., Dean, C., Broere, F., van Eden, W., Bijlsma, J. W. J., Lafeber, F. P. J. G., & van Roon, J. A. G. (2011) · Arthritis & Rheumatism · doi:10.1002/art.30336 · Cited by 62
Translating Molecular Insights in Autoimmunity into Effective Therapy
Feldmann, M. (2008) · Annual Review of Immunology · doi:10.1146/annurev-immunol-082708-100732 · Cited by 62
B cell depletion in the treatment of multiple sclerosis
Myhr, K., Torkildsen, Ø., Lossius, A., Bø, L., & Holmøy, T. (2019) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2019.1568407 · Cited by 64
Is there a role for rituximab in the treatment of idiopathic childhood nephrotic syndrome?
Smith, G. C. (2007) · Pediatric Nephrology · doi:10.1007/s00467-006-0427-5 · Cited by 63
Modeling human arthritic diseases in nonhuman primates.
Vierboom, M., Jonker, M., Bontrop, R. E., & Hart, B. A. ‘. (2005) · Arthritis Research & Therapy · doi:10.1186/ar1773 · Cited by 61
Wieland, A., Shashidharamurthy, R., Kamphorst, A. O., Han, J., Aubert, R. D., Choudhury, B., Stowell, S. R., Lee, J., Punkosdy, G. A., Shlomchik, M. J., et al. (2015) · Immunity · doi:10.1016/j.immuni.2015.01.009 · Cited by 62
Rituximab-induced Elimination of Acquired Angioedema Due to C1-Inhibitor Deficiency
Levi, M. M., Hack, C. E., & van Oers, M. H. J. (2006) · The American Journal of Medicine · doi:10.1016/j.amjmed.2005.09.018 · Cited by 61
Fluge, Ø., & Mella, O. (2009) · BMC Neurology · doi:10.1186/1471-2377-9-28 · Cited by 62
Chu, S. Y., Yeter, K. C., Kotha, R., Pong, E., Miranda, Y., Phung, S., Chen, H., Lee, S., Leung, I., Bonzon, C., et al. (2013) · Arthritis & Rheumatology · doi:10.1002/art.38334 · Cited by 61
Gremese, E., Alivernini, S., Tolusso, B., Zeidler, M. P., & Ferraccioli, G. (2019) · Journal of Leukocyte Biology · doi:10.1002/jlb.5ru0519-145r · Cited by 62
New Reagents on the Horizon for Immune Tolerance
Clair, E. W. S., Turka, L. A., Saxon, A., Matthews, J. B., Sayegh, M. H., Eisenbarth, G. S., & Bluestone, J. A. (2006) · Annual Review of Medicine · doi:10.1146/annurev.med.58.061705.145449 · Cited by 63
Rituximab: Beyond Simple B Cell Depletion
Kessel, A., Rosner, I., & Toubi, E. (2008) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-008-8074-1 · Cited by 62
Titanji, K. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01851 · Cited by 61
Orvain, C., Boulch, M., Bousso, P., Allanore, Y., & Avouac, J. (2021) · Arthritis & Rheumatology · doi:10.1002/art.41812 · Cited by 62
Off-label use of rituximab in systemic lupus erythematosus: a systematic review
Murray, E. C., & Perry, M. E. (2010) · Clinical Rheumatology · doi:10.1007/s10067-010-1387-5 · Cited by 61
Wendler, J., Burmester, G. R., Sörensen, H., Krause, A., Richter, C., Tony, H., Rubbert‐Roth, A., Bartz‐Bazzanella, P., Wassenberg, S., Haug-Rost, I., et al. (2014) · Arthritis Research & Therapy · doi:10.1186/ar4521 · Cited by 61
Lino, A. C., Dörner, T., Bar‐Or, A., & Fillatreau, S. (2015) · Immunological Reviews · doi:10.1111/imr.12374 · Cited by 64
Preventive Effect of Lactobacillus helveticus SBT2171 on Collagen-Induced Arthritis in Mice
Yamashita, M., Matsumoto, K., Endo, T., Ukibe, K., Hosoya, T., Matsubara, Y., Nakagawa, H., Sakai, F., & Miyazaki, T. (2017) · Frontiers in Microbiology · doi:10.3389/fmicb.2017.01159 · Cited by 61
B lymphocytes and lupus nephritis: New insights into pathogenesis and targeted therapies
Bhat, P., & Radhakrishnan, J. (2007) · Kidney International · doi:10.1038/sj.ki.5002663 · Cited by 61
B cells drive neuropathic pain–related behaviors in mice through IgG–Fc gamma receptor signaling
Lacagnina, M. J., Willcox, K. F., Boukelmoune, N., Bavencoffe, A., Sankaranarayanan, I., Barratt, D. T., Zuberi, Y. A., Dayani, D., Chavez, M. V., Lu, J. T., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.adj1277 · Cited by 60
Bezzio, C., Corte, C. D., Vernero, M., Luna, I. D., Manes, G., & Saibeni, S. (2022) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848221115312 · Cited by 60
Activated B cells in autoimmune diseases: the case for a regulatory role
Anderton, S. M., & Fillatreau, S. (2008) · Nature Clinical Practice Rheumatology · doi:10.1038/ncprheum0950 · Cited by 59
Generalizability of Patients With Rheumatoid Arthritis in Biologic Agent Clinical Trials
Vashisht, P., Sayles, H., Cannella, A. C., Mikuls, T., & Michaud, K. (2016) · Arthritis care & research · doi:10.1002/acr.22860 · Cited by 57
Management of rheumatoid arthritis: Impact and risks of various therapeutic approaches
Negrei, C., Bojinca, V. C., Balanescu, A. R., Bojincă, M., Baconi, D. L., Spandidos, D. A., Tsatsakis, A. M., & Stan, M. (2016) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2016.3045 · Cited by 59
Tak, P. P., Doorenspleet, M. E., de Hair, M. J. H., Klarenbeek, P. L., van Beers-Tas, M. H., van Kampen, A. H. C., van Schaardenburg, D., Gerlag, D. M., Baas, F., & de Vries, N. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2017-211351 · Cited by 59
RetractedPetereit, H.-F., Moeller‐Hartmann, W., Reske, D., & RUBBERT, A. (2007) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.2007.00958.x · Cited by 59
Therapeutic approaches for celiac disease
Plugis, N. M., & Khosla, C. (2015) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2015.04.005 · Cited by 59
Am“B”valent: anti-CD20 antibodies unravel the dual role of B cells in immunopathogenesis
Thaunat, O., Morélon, E., & Defrance, T. (2010) · Blood · doi:10.1182/blood-2010-01-266668 · Cited by 59
B cells—Masters of the immunoverse
Vaughan, A. T., Roghanian, A., & Cragg, M. S. (2010) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2010.12.005 · Cited by 59
Mechanism by which HLA-DR4 regulates sex-bias of arthritis in humanized mice
Behrens, M. D., Trejo, T., Luthra, H. S., Griffiths, M. M., David, C. S., & Taneja, V. (2010) · Journal of Autoimmunity · doi:10.1016/j.jaut.2009.12.007 · Cited by 59
Jackson, S. W., Kolhatkar, N. S., & Rawlings, D. J. (2015) · Current Opinion in Immunology · doi:10.1016/j.coi.2015.01.018 · Cited by 59
Vital, E. M. J., Dass, S., Buch, M. H., Rawstron, A. C., & Emery, P. (2014) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-204544 · Cited by 59
Self-citation
Metadata
- Authors
- Edwards, J. C. W., Szczepański, L., Szechiński, J., Filipowicz-Sosnowska, A., Emery, P., Close, D. R., Stevens, R. M., & Shaw, T.
- Affiliations
- University College London (GB)
- University of Wrocław (PL)
- Roche (United Kingdom) (GB)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2004-06-17
- Volume
- 350
- Issue
- 25
- Pages
- 2572-2581
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2118994799
- Cited by
- 2,623
- References
- 21
- Citations by year
- 2026: 65 · 2025: 69 · 2024: 76 · 2023: 62 · 2022: 61 · 2021: 85 · 2020: 87 · 2019: 85 · 2018: 103 · 2017: 112 · 2016: 96 · 2015: 103 · 2014: 129 · 2013: 133 · 2012: 133
- FWCI
- 109.25
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Topics
- Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
- Health Sciences › Medicine › Hematology › Autoimmune and Inflammatory Disorders Research
- Health Sciences › Medicine › Complementary and alternative medicine › Natural Compounds in Disease Treatment
- Keywords
- rheumatoid arthritis, rituximab, B-cell depletion, cyclophosphamide, methotrexate, combination therapy, adverse events, serious infections, immunoglobulin levels, treatment-resistant rheumatoid arthritis, ACR response criteria, EULAR response criteria, maintenance therapy, relapse prevention, long-term follow-up, drug efficacy
- MeSH terms
- Rituximab, Antibodies, Monoclonal, Arthritis, Rheumatoid, B-Lymphocytes, Bacterial Infections, Cyclophosphamide, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Immunosuppressive Agents, Male, Methotrexate, Middle Aged, Antirheumatic Agents, Antigens, CD20, Antibodies, Monoclonal, Murine-Derived
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
